NeuroVive Pharmaceutical AB (OM:NVP) agreed to acquire 10% stake in Isomerase Therapeutics Ltd. for SEK 15 million.

NeuroVive Pharmaceutical AB (OM:NVP) agreed to acquire 10% stake in Isomerase Therapeutics Ltd. for SEK 15 million on January 13, 2015. The acquisition will be executed in two steps. The first step in the acquisition was executed on January 13, 2016 when NeuroVive acquired approximately 5% shares in Isomerase with payment of its 0.74 million shares.

The next step in the acquisition will be completed later this year where NeuroVive will acquire approximately 5% further of the shares in Isomerase as a cash payment of £0.5 million (SEK 6.8 million). The conversions have been made using oanda.com as of January 14, 2016.